Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30820045 | 1.00 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2C9CYP2C19TSHR | |
| Hydrochloric Acid SCHEMBL15776039 | 0.98 | ALDH1A1 (0.48) | ALDH1A1CYP1A2CYP2C9CYP2C19TSHR | |
| SCHEMBL4150801 | 0.81 | MTNR1A (0.41) | ALDH1A1CYP1A2CYP2C9CYP2C19TDP1 | |
| SCHEMBL25155499 | 0.80 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2C9CYP2C19TSHR | |
| SCHEMBL4822950 | 0.80 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2C9CYP2C19TSHR | |
| SCHEMBL30344537 | 0.80 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2C9CYP2C19TSHR | |
| SCHEMBL9391087 | 0.80 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2C9CYP2C19TSHR | |
| SCHEMBL27346677 | 0.79 | ALDH1A1 (0.38) | ALDH1A1CYP1A2CYP2C9CYP2C19TSHR | |
| SCHEMBL7595550 | 0.79 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2C9CYP2C19TSHR | |
| Hydrochloric Acid SCHEMBL10821050 | 0.78 | ALDH1A1 (0.48) | ALDH1A1CYP1A2CYP2C9CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150299143-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-22 | — | — | US | claimed |
| US-20240182444-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-06 | — | — | US | disclosed |
| WO-2024086111-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-11925643-B2 | Toll-like receptor 4 (TLR4) inhibitors and use thereof | MOR RESEARCH APPLICATIONS LTD. (IL) | 2024-03-12 | — | — | US | disclosed |
| WO-2023064493-A1 | COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES | Clear Creek Bio, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
| US-20210196717-A1 | TOLL-LIKE RECEPTOR 4 (TLR4) INHIBITORS AND USE THEREOF | BAR-ILAN UNIVERSITY (IL) | 2021-07-01 | — | — | US | disclosed |
| US-20150299143-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-22 | — | — | US | disclosed |
| EP-2925746-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014086663-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |
| US-7365223-B2 | Method for selective targeting of apoptotic cells and small molecule ligands used thereof | NST NEUROSURVIVAL TECHNOLOGIES LTD (IL) | 2008-04-29 | — | — | US | disclosed |
| US-7365223-B2 | Method for selective targeting of apoptotic cells and small molecule ligands used thereof | NST NEUROSURVIVAL TECHNOLOGIES LTD (IL) | 2008-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299143-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | HDAC7, PSMB7, IKZF3 | ALDH1A1 1540/4885CYP1A2 932/4885CYP2C9 1107/4885 |
| US-11925643-B2 | Toll-like receptor 4 (TLR4) inhibitors and use thereof | TLR4, TLR1, TLR3 | ALDH1A1 4799/4885CYP1A2 4840/4885CYP2C9 4720/4885 |
| US-20240182444-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | ALDH1A1 2039/4885CYP1A2 3530/4885CYP2C9 2985/4885 |
| US-20210196717-A1 | TOLL-LIKE RECEPTOR 4 (TLR4) INHIBITORS AND USE THEREOF | TLR4, TLR1, TLR3 | ALDH1A1 4799/4885CYP1A2 4840/4885CYP2C9 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.